Controlled Clinical Trials

DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 10, 1989

Contents

RICHARD SIMON
Optimal Two-Stage Designs for Phase II Clinical Trials 1

BARRY DAVIS, M. DONALD BLAUFOX, C. MORTON HAWKINS, HERBERT G. LANGFORD, ALBERT OBERMAN, CHARLES SWENCIONIS, SYLVIA WASSERTHEIL-SMOLLER, JUDY WYLIE-ROSETT, and NEAL ZIMBALDI
Trial of Antihypertensive Interventions and Management 11

PETER C. GØTZSCHE
Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis 31

GREGORY G. ENAS, BRUCE E. DORNSEIF, CHARLES B. SAMPSON, FRANK W. ROCKHOLD, and JULIE WUU
Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry 57

DAVID SALSBURG
Use of Restricted Significance Tests in Clinical Trials: Beyond the One- Versus Two-Tailed Controversy 71

THE DCCT RESEARCH GROUP
Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial 83

GORDON PLEDGER
The Role of a Placebo-Treated Control Group in Combination Drug Trials 97

BARBARA S. HAWKINS
Perusing the Literature 108

Book Review 125

Announcement 127

Erratum
Wei, LJ and Lachin, JM: Properties of the Urn Randomization in Clinical Trials 127

Controlled Clinical Trials

DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 10, 1989

Contents

RICHARD SIMON
Optimal Two-Stage Designs for Phase II Clinical Trials 1

BARRY DAVIS, M. DONALD BLAUFOX, C. MORTON HAWKINS, HERBERT G. LANGFORD, ALBERT OBERMAN, CHARLES SWENCIONIS, SYLVIA WASSERTHEIL-SMOLLER, JUDY WYLIE-ROSETT, and NEAL ZIMBALDI
Trial of Antihypertensive Interventions and Management 11

PETER C. GØTZSCHE
Methodology and Overt and Hidden Bias in Reports of 196 Double-Blind Trials of Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis 31

GREGORY G. ENAS, BRUCE E. DORNSEIF, CHARLES B. SAMPSON, FRANK W. ROCKHOLD, and JULIE WUU
Monitoring Versus Interim Analysis of Clinical Trials: A Perspective from the Pharmaceutical Industry 57

DAVID SALSBURG
Use of Restricted Significance Tests in Clinical Trials: Beyond the One- Versus Two-Tailed Controversy 71

THE DCCT RESEARCH GROUP
Implementation of a Multicomponent Process to Obtain Informed Consent in the Diabetes Control and Complications Trial 83

GORDON PLEDGER
The Role of a Placebo-Treated Control Group in Combination Drug Trials 97

BARBARA S. HAWKINS
Perusing the Literature 108

Book Review 125

Announcement 127

Erratum
Wei, LJ and Lachin, JM: Properties of the Urn Randomization in Clinical Trials 127

LAURENCE FREEDMAN, RICHARD SYLVESTER, and DAVID P. BYAR
Using Permutation Tests and Bootstrap Confidence Limits to Analyze Repeated Events Data from Clinical Trials 129

DAVID R. BRISTOL
Designing Clinical Trials for Two-sided Multiple Comparisons with a Control 142

E. ROBERT GREENBERG, JOHN A. BARON, MARGUERITE M. STEVENS, THÉRÈSE A. STUKEL, JACK S. MANDEL, STEVEN K. SPENCER, PETER M. ELIAS, NICHOLAS LOWE, DAVID N. NIERENBERG, GARRETT BAYRD, J. CORWIN VANCE, and the SKIN CANCER PREVENTION STUDY GROUP
The Skin Prevention Study: Design of a Clinical Trial of Beta-Carotene Among Persons at High Risk for Nonmelanoma Skin Cancer 153

SHRIKANT I. BANGDIWALA, RICHARD COHN, CAROL HAZARD, C.E. DAVIS, and RONALD J. PRINEAS
Comparisons of Cause of Death Verification Methods and Costs in the Lipid Research Clinics Program Mortality Follow-up Study 167

STEVEN N. GOODMAN
Meta-analysis and Evidence 188

DAVID ZUCKER and SALIM YUSUF
The Likelihood Ratio Versus the *p*-Value in Meta-Analysis: Where is the Evidence? Comment on the Paper by S.N. Goodman 205

STEVEN N. GOODMAN
Response to Commentary of Zucker and Yusuf 209

BARBARA S. HAWKINS
Perusing the Literature 211

Letters to the Editor
JOSEPH L. FLEISS
One-tailed Versus Two-tailed Tests: Rebuttal 227

CLAUDE LENFANT
Multicenter Investigator-initiated Trials 228

DENNIS O. DIXON
Assessing New Cancer Treatment 231

TIMOTHY M. MORGAN
Response to Dixon: Analysis of Duration of Response 234

Announcement 236

JOSEPH L. FLEISS
A Critique of Recent Research on the Two-Treatment Crossover Design 237

VALERIE MIKÉ
Philosophers Assess Randomized Clinical Trials: The Need for Dialogue 244

JEAN-PIERRE BOISSEL, JEAN BLANCHARD, EDOUARD PANAK, JEAN-CLAUDE PEYRIEUX, and HENRY SACKS
Considerations for the Meta-analysis of Randomized Clinical Trials: Summary of a Panel Discussion 254

DORICE M. JASPERSE and SUSAN W. AHMED
The Mid-Atlantic Oncology Program's Comparison of Two Data Collection Methods 282

ELINA HEMMINKI, ANNE USKI, PÄIVIKKI KOPENEN, and ULLA RIMPELÄ
Iron Supplementation During Pregnancy—Experiences of a Randomized Trial Relying on Health Service Personnel 290

Society for Clinical Trials: Officers, Board of Directors, Program Committee Chairmen, and Secretariat 299

Final Program: Tenth Annual Meeting of the Society for Clinical Trials 301

Abstracts: Tenth Annual Meeting of the Society for Clinical Trials 316

Announcements 355

Erratum 356

LAURENCE S. FREEDMAN and DAVID J. SPIEGELHALTER
Comparison of Bayesian with Group Sequential Methods for Monitoring Clinical Trials 357

ROWAN T. CHLEBOWSKI, GEORGE L. BLACKBURN, DANIEL W. NIXON, PETER JOCHIMSEN, EDWARD F. SCANLON, WILLIAM INSULL, Jr., I. MARILYN BUZZARD, ERNEST L. WYNDER, and ROBERT ELASHOFF
Unpublished Data Summaries and the Design and Conduct of Clinical Trials: The Nutrition Adjuvant Study Experience and Commentary 368

MOHAMED A. A. MOUSSA
Exact, Conditional, and Predictive Power in Planning Clinical Trials 378

BRENT A. BLUMENSTEIN
The Relational Database Model and Multiple Multicenter Clinical Trials 386

ROMAN JAESCHKE, JOEL SINGER, and GORDON H. GUYATT
Measurement of Health Status: Ascertaining the Minimal Clinically Important Difference 407

YVONNE A. SIEVERT, SALLY F. SCHAKEL, and I. MARILYN BUZZARD
Maintenance of a Nutrient Database for Clinical Trials 416

RICHARD PETO and IAIN CHALMERS
Obituary: Archie Cochrane (1909–1988) 426

Archie Cochrane in His Own Words: Selections arranged from his 1972 Introduction to "Effectiveness and Efficiency: Random Reflections on the Health Services" 428

Announcement 434

Erratum 435

Author Index to Volume 10 436

Subject Index to Volume 10 437

Volume Contents

The Hypertension Prevention Trial: Design, Methods, and Baseline Results (Hypertension Prevention Trial Research Group; Guest Editors: Curtis L. Meinert, James Tonascia, and Susan Tonascia)

CURTIS L. MEINERT, NEMAT O. BORHANI, and HERBERT G. LANGFORD
Chapter 1. Design, Methods, and Rationale in the Hypertension Prevention Trial 1S

NEMAT O. BORHANI, JAMES TONASCIA, DAVID G. SCHLUNDT, RONALD J. PRINEAS, and JOAN L. JEFFERYS
Chapter 2. Recruitment in the Hypertension Prevention Trial 30S

KATHLEEN M. BROWN, ALBERT OBERMAN, MARK L. VAN NATTA, and JEAN L. FORSTER
Chapter 3. Baseline Characteristics in the Hypertension Prevention Trial 40S

ROBERT W. JEFFERY, SUSAN TONASCIA, WENDY BJORNSON-BENSON, DAVID G. SCHLUNDT, and CAROLYN SUGARS
Chapter 4. Treatment in the Hypertension Prevention Trial 65S

GERARD J. PRUD'HOMME, PAUL L. CANNER, and JEFFREY A. CUTLER
Chapter 5. Quality Assurance and Monitoring in the Hypertension Prevention Trial 84S

References 95S

Appendices 102S

Selected Papers from the Sixth International Symposium on Long-Term Clinical Trials (Guest Co-Editors: Joerg Hasford and Genell Knatterud; Guest Associate Co-Editors: Marian Fisher and Dorle Messerer)

JOERG HASFORD, GENELL KNATTERUD, MARIAN FISHER, and DORLE MESSERER
Introduction 119S

Impact of Clinical Trials
JEAN-PIERRE BOISSEL
Impact of Randomized Clinical Trials on Medical Practices 120S

CHRISTIAN R. KLIMT
Varied Acceptance of Clinical Trial Results 135S

Design and Methods of Large Studies with Simple Protocols and Primary Prevention Trials
CHARLES H. HENNEKENS and JULIE E. BURING
Methodologic Considerations in the Design and Conduct of Randomized Trials: The U.S. Physicians' Health Study 142S

JACOBUS LUBSEN and JAN G.P. TIJSSEN
Large Trials with Simple Protocols: Indications and Contraindications 151S

Subgroup Analysis
MICHAEL BEACH and PAUL MEIER
Choosing Covariates in the Analysis of Clinical Trials 161S

BERTHOLD SCHNEIDER
Analysis of Clinical Trial Outcomes: Alternative Approaches to Subgroup Analysis 176S

MARC E. BUYSE
Analysis of Clinical Trial Outcomes: Some Comments on Subgroup Analyses 187S

Quality of Life in Long-Term Clinical Trials
NEIL K. AARONSON
Quality of Life Assessment in Clinical Trials: Methodologic Issues 195S

Aspects of Sequential Monitoring
STUART J. POCOCK and MICHAEL D. HUGHES
Practical Problems in Interim Analyses, with Particular Regard to Estimation 209S

WOLFGANG KOEPCKE
Analyses of Group Sequential Clinical Trials 222S

Clinical Trials and Regulation
URSULA GUNDERT-REMY
The Role of Clinical Trials in Drug Regulation 231S

JERE E. GOYAN
The "Trials" of a Long-Term Clinical Trial: The Ticlopidine Aspirin Stroke Study and the Canadian–American Ticlopidine Study 236S

Alternative Strategies for Assessing Thrombolysis in Cardiovascular Disease
GENELL L. KNATTERUD
Thrombolysis in Myocardial Infarction (TIMI) Randomized Studies Versus TIMI Open Label Studies 245S

Meta-analysis
CURTIS L. MEINERT
Meta-analysis: Science or Religion? 257S